These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 35660765)

  • 1. A new AI-assisted scoring system for PD-L1 expression in NSCLC.
    Huang Z; Chen L; Lv L; Fu CC; Jin Y; Zheng Q; Wang B; Ye Q; Fang Q; Li Y
    Comput Methods Programs Biomed; 2022 Jun; 221():106829. PubMed ID: 35660765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer.
    Wu J; Liu C; Liu X; Sun W; Li L; Gao N; Zhang Y; Yang X; Zhang J; Wang H; Liu X; Huang X; Zhang Y; Cheng R; Chi K; Mao L; Zhou L; Lin D; Ling S
    Mod Pathol; 2022 Mar; 35(3):403-411. PubMed ID: 34518630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Deep Learning-Based Assay for Programmed Death Ligand 1 Immunohistochemistry Scoring in Non-Small Cell Lung Carcinoma: Does it Help Pathologists Score?
    Ito H; Yoshizawa A; Terada K; Nakakura A; Rokutan-Kurata M; Sugimoto T; Nishimura K; Nakajima N; Sumiyoshi S; Hamaji M; Menju T; Date H; Morita S; Bise R; Haga H
    Mod Pathol; 2024 Jun; 37(6):100485. PubMed ID: 38588885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Validation of Artificial Intelligence-Powered PD-L1 Tumor Proportion Score Interpretation for Immune Checkpoint Inhibitor Response Prediction in Non-Small Cell Lung Cancer.
    Kim H; Kim S; Choi S; Park C; Park S; Pereira S; Ma M; Yoo D; Paeng K; Jung W; Park S; Ock CY; Lee SH; Choi YL; Chung JH
    JCO Precis Oncol; 2024 May; 8():e2300556. PubMed ID: 38723233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Artificial intelligence-powered programmed death ligand 1 analyser reduces interobserver variation in tumour proportion score for non-small cell lung cancer with better prediction of immunotherapy response.
    Choi S; Cho SI; Ma M; Park S; Pereira S; Aum BJ; Shin S; Paeng K; Yoo D; Jung W; Ock CY; Lee SH; Choi YL; Chung JH; Mok TS; Kim H; Kim S
    Eur J Cancer; 2022 Jul; 170():17-26. PubMed ID: 35576849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing deep learning and pathologist quantification of cell-level PD-L1 expression in non-small cell lung cancer whole-slide images.
    van Eekelen L; Spronck J; Looijen-Salamon M; Vos S; Munari E; Girolami I; Eccher A; Acs B; Boyaci C; de Souza GS; Demirel-Andishmand M; Meesters LD; Zegers D; van der Woude L; Theelen W; van den Heuvel M; Grünberg K; van Ginneken B; van der Laak J; Ciompi F
    Sci Rep; 2024 Mar; 14(1):7136. PubMed ID: 38531958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of a supervised deep learning algorithm for automated whole-slide programmed death-ligand 1 tumour proportion score assessment in non-small cell lung cancer.
    Hondelink LM; Hüyük M; Postmus PE; Smit VTHBM; Blom S; von der Thüsen JH; Cohen D
    Histopathology; 2022 Mar; 80(4):635-647. PubMed ID: 34786761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Pipeline for Evaluation of Machine Learning/Artificial Intelligence Models to Quantify Programmed Death Ligand 1 Immunohistochemistry.
    Knudsen BS; Jadhav A; Perry LJ; Thagaard J; Deftereos G; Ying J; Brintz BJ; Zhang W
    Lab Invest; 2024 Jun; 104(6):102070. PubMed ID: 38677590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer.
    Pan B; Kang Y; Jin Y; Yang L; Zheng Y; Cui L; Sun J; Feng J; Li Y; Guo L; Liang Z
    J Transl Med; 2021 Jun; 19(1):249. PubMed ID: 34098964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC).
    De Marchi P; Leal LF; Duval da Silva V; da Silva ECA; Cordeiro de Lima VC; Reis RM
    J Clin Pathol; 2021 Nov; 74(11):735-740. PubMed ID: 33589532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer.
    Jasani B; Bänfer G; Fish R; Waelput W; Sucaet Y; Barker C; Whiteley JL; Walker J; Hovelinck R; Diezko R
    Diagn Pathol; 2020 Apr; 15(1):37. PubMed ID: 32303234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A preliminary study on the diagnostic performance of the uPath PD-L1 (SP263) artificial intelligence (AI) algorithm in patients with NSCLC treated with PD-1/PD-L1 checkpoint blockade.
    Cortellini A; Zampacorta C; De Tursi M; Grillo LR; Ricciardi S; Bria E; Martini M; Giusti R; Filetti M; Dal Mas A; Russano M; Dall'Olio FG; Buttitta F; Marchetti A
    Pathologica; 2024 Aug; 116(4):222-231. PubMed ID: 39377504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments.
    Rüschoff J; Kumar G; Badve S; Jasani B; Krause E; Rioux-Leclercq N; Rojo F; Martini M; Cheng L; Tretiakova M; Mitchell C; Anders RA; Robert ME; Fahy D; Pyle M; Le Q; Yu L; Glass B; Baxi V; Babadjanova Z; Pratt J; Brutus S; Karasarides M; Hartmann A
    Virchows Arch; 2024 Apr; 484(4):597-608. PubMed ID: 38570364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An artificial intelligence-powered PD-L1 combined positive score (CPS) analyser in urothelial carcinoma alleviating interobserver and intersite variability.
    Lee KS; Choi E; Cho SI; Park S; Ryu J; Puche AV; Ma M; Park J; Jung W; Ro J; Kim S; Park G; Song S; Ock CY; Choe G; Park JH
    Histopathology; 2024 Jul; 85(1):81-91. PubMed ID: 38477366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Automated tumor proportion score analysis for PD-L1 (22C3) expression in lung squamous cell carcinoma.
    Liu J; Zheng Q; Mu X; Zuo Y; Xu B; Jin Y; Wang Y; Tian H; Yang Y; Xue Q; Huang Z; Chen L; Gu B; Hou X; Shen L; Guo Y; Li Y
    Sci Rep; 2021 Aug; 11(1):15907. PubMed ID: 34354151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interobserver agreement in programmed cell death-ligand 1 immunohistochemistry scoring in nonsmall cell lung carcinoma cytologic specimens.
    Sinclair W; Kobalka P; Ren R; Beshai B; Lott Limbach AA; Wei L; Mei P; Li Z
    Diagn Cytopathol; 2021 Feb; 49(2):219-225. PubMed ID: 33104298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 Assessment in Needle Core Biopsies of Non-Small Cell Lung Cancer: Interpathologist Agreement and Potential Associated Histopathological Features.
    Hacihasanoglu E; Bambul Sigirci B; Usul G; Savli TC
    Turk Patoloji Derg; 2024; 40(1):37-44. PubMed ID: 37614090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Artificial intelligence enhances whole-slide interpretation of PD-L1 CPS in triple-negative breast cancer: A multi-institutional ring study.
    Li J; Dong P; Wang X; Zhang J; Zhao M; Shen H; Cai L; He J; Han M; Miao J; Liu H; Yang W; Han X; Liu Y
    Histopathology; 2024 Sep; 85(3):451-467. PubMed ID: 38747491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab.
    Baxi V; Lee G; Duan C; Pandya D; Cohen DN; Edwards R; Chang H; Li J; Elliott H; Pokkalla H; Glass B; Agrawal N; Lahiri A; Wang D; Khosla A; Wapinski I; Beck A; Montalto M
    Mod Pathol; 2022 Nov; 35(11):1529-1539. PubMed ID: 35840720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.